Supplementary Materials

Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide

List of Contents

Supplementary Table 1. STROBE statement
Supplementary Table 2. Baseline characteristics of 4,309 untreated patients with chronic hepatitis B.
Supplementary Table 3. Comparison of baseline characteristics between patients with and without the development of major adverse cardiovascular events (MACE)
Supplementary Table 4. Baseline characteristics of patients who did not administer any lipid-lowering agents at baseline and during the study period
Supplementary Table 5. Changes in the lipid profiles during the study period in patients who did not receive any lipid-lowering agents at baseline or during the study period
Supplementary Figure 1. Serial changes in the lipid profiles of the entire study population
  (A) Total cholesterol
  (B) High-density lipoprotein
  (C) Low-density lipoprotein
  (D) Triglyceride
  (E) Total cholesterol/high-density lipoprotein ratio
Supplementary Figure 2. Serial changes in the lipid profiles of patients who did not receive lipid-lowering agents
  (A) Total cholesterol
  (B) High-density lipoprotein
  (C) Low-density lipoprotein
  (D) Triglyceride
  (E) Total cholesterol/high-density lipoprotein ratio
Supplementary Table 1. STROBE statement

<table>
<thead>
<tr>
<th>Item No.</th>
<th>Recommendation</th>
<th>Section &amp; Page No.</th>
</tr>
</thead>
</table>
| **Title and abstract** | 1  
(a) Indicate the study's design with a commonly used term in the title or the abstract.  
(b) Provide in the abstract an informative and balanced summary of what was done and what was found. | Abstract, Methods |
| **Introduction** | 2  
Explain the scientific background and rationale for the investigation being reported. | Introduction, page 1 |
| **Objectives** | 3  
State specific objectives, including any prespecified hypotheses. | Introduction, page 2 |
| **Methods** | 4  
Present the key elements of study design early in the paper. | Methods, page 3 |
| **Setting** | 5  
Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection. | Methods, page 3 |
| **Participants** | 6  
(a) Cohort study—Give the eligibility criteria and the sources and methods of selection of the participants. Describe the methods of follow-up.  
Case-control study—Give the eligibility criteria and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls.  
Cross-sectional study—Give the eligibility criteria and the sources and methods of selection of the participants.  
(b) Cohort study—For matched studies, give matching criteria and the number of exposed and unexposed cases.  
Case-control study—For matched studies, give matching criteria and the number of controls per case. | Methods, page 3 |
| **Variables** | 7  
Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. | Methods, page 3 |
| **Data sources/ measurement** | 8*  
For each variable of interest, give sources of data and details of the methods of assessment (measurement). Describe the comparability of a assessment methods if there is more than one group. | Methods, page 3 |
| **Bias** | 9  
Describe any efforts to address potential sources of bias. | Methods, page 4 |
| **Study size** | 10  
Explain how the study size was arrived at. | Not applicable |
| **Quantitative variables** | 11  
Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why. | Methods, page 4 |
| **Statistical methods** | 12  
(a) Describe all statistical methods, including those used to control for confounding.  
(b) Describe any methods used to examine subgroups and interactions.  
(c) Explain how missing data were addressed.  
(d) Cohort study—If applicable, explain how the loss to follow-up was addressed.  
Case-control study—If applicable, explain how the matching of cases and controls was addressed.  
Cross-sectional study—If applicable, describe how the analytical methods took the sampling strategy into account. | Methods, page 4 |
## Supplementary Table 1. Continued

<table>
<thead>
<tr>
<th>Item No.</th>
<th>Recommendation</th>
<th>Section &amp; Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants 13*</td>
<td>(e) Describe any sensitivity analyses.</td>
<td>Methods, page 4</td>
</tr>
<tr>
<td></td>
<td>(a) Report the numbers of individuals at each stage of the study—e.g., the number of potentially eligible cases and those examined for eligibility, confirmed to be eligible, included in the study, completed follow-up, and analyzed.</td>
<td>Results, page 4</td>
</tr>
<tr>
<td></td>
<td>(b) Give reasons for non-participation at each stage.</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>(c) Consider use of a flow diagram.</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Descriptive data 14*</td>
<td>(a) Give the summary characteristics of study participants (e.g., demographic, clinical, and social data) and information regarding exposure and potential confounding variables.</td>
<td>Results, page 4</td>
</tr>
<tr>
<td></td>
<td>(b) Indicate the number of participants with missing data for each variable of interest.</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>(c) Cohort study—Summarize the follow-up time (e.g., average and total amount).</td>
<td>Results, page 4</td>
</tr>
<tr>
<td>Outcome data 15*</td>
<td>Cohort study—Report the numbers of outcome events or summary measures over time.</td>
<td>Results, page 4 &amp; 7</td>
</tr>
<tr>
<td></td>
<td>Case-control study—Report the numbers for each exposure category or the summary measures of exposure.</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>Cross-sectional study—Report the numbers of outcome events or summary measures.</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Main results 16</td>
<td>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included.</td>
<td>Results, page 4 &amp; 7</td>
</tr>
<tr>
<td></td>
<td>(b) Report category boundaries when continuous variables are categorized.</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period.</td>
<td>Results, pp page 4 &amp; 7</td>
</tr>
<tr>
<td>Other analyses 17</td>
<td>Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses.</td>
<td>Results, page 7</td>
</tr>
<tr>
<td>Key results 18</td>
<td>Summarize key results with reference to study objectives.</td>
<td>Discussion, page 9</td>
</tr>
<tr>
<td>Limitations 19</td>
<td>Discuss the limitations of the study, considering any potential sources of bias or imprecision. Discuss both the direction and magnitude of any potential bias.</td>
<td>Discussion, page 13 &amp; 14</td>
</tr>
<tr>
<td>Interpretation 20</td>
<td>Give a cautious overall interpretation of results considering the study objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.</td>
<td>Discussion, page 9 &amp; 13</td>
</tr>
<tr>
<td>Generalizability 21</td>
<td>Discuss the generalizability (external validity) of the study results.</td>
<td>Discussion, page 14</td>
</tr>
<tr>
<td>Other information Funding 22</td>
<td>Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based.</td>
<td>Acknowledgements</td>
</tr>
</tbody>
</table>

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.